In addition to demonstrating that these plasma biomarkers are associated with future neurodegenerative and cognitive trajectories, we show that the extent to which GFAP and pTau-181 predict brain atrophy and cognitive decline depends on the burden of brain amyloid. The gene discussed is GFAP; the disease is Brain atrophy.